The National Institutes of Health (NIH) was shocked to discover that many of its scientists had not adhered to the ethical restrictions imposed and were making outside income from private consulting deals with drug and biotechnology companies. NIH put new ethics rules in place after last year’s discovery and now ban all outside income from drug and biotechnology companies. An estimate of 40% of the scientists conducting hands-on research at NIH are now looking for alternative employment. In the enactment of the new rules, officials emphasized that the new ethic rules will boost the agency’s credibility with the public. With pharmaceutical companies attempting to exert influence on both researchers and doctors, NIH will certainly gain integrity by staying far away from such monetary influence.
To read the full article.